FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to the monoclonal antibody ACMIS-3.
EFFECT: invention makes it possible to effectively treat diseases associated with the factor ACMIS-3.
3 cl, 5 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MONOCLONAL ANTIBODY AGAINST THE C-TERMINAL FRAGMENT OF ANTI-MULLERIAN HORMONE | 2021 |
|
RU2764795C1 |
| MONOCLONAL ANTIBODIES TO C-END FRAGMENT OF ANTI-MULLER HORMONE | 2018 |
|
RU2765689C2 |
| MONOCLONAL ANTIBODY TO RDB FRAGMENT IN COMPOSITION OF SARS-COV-2 S PROTEIN | 2020 |
|
RU2744274C1 |
| ANTIBODIES SPECIFIC TO HUMAN NECTIN-4 | 2019 |
|
RU2825839C2 |
| ANTIBODIES SPECIFIC TO HUMAN POLIOVIRUS RECEPTOR (PVR) | 2017 |
|
RU2756275C2 |
| HUMAN NECTIN-2 SPECIFIC ANTIBODIES | 2020 |
|
RU2820275C2 |
| MONOCLONAL ANTI-IDIOTYPIC ANTIBODY AI-G1, HAVING ANTIGENIC PROPERTIES OF MORPHINE | 2019 |
|
RU2717989C1 |
| MONOCLONAL ANTIBODIES TO INTERLEUKIN-31 FOR VETERINARY USE | 2019 |
|
RU2795411C2 |
| ANAPHYLATOXIN C5A ANTIBODIES TO HUMAN | 2019 |
|
RU2731516C1 |
| COMPOSITIONS CONTAINING ANTI-SEAMS 1 AND ANTI-PD ANTIBODIES FOR CANCER THERAPY | 2014 |
|
RU2697522C1 |
Authors
Dates
2022-04-14—Published
2021-04-05—Filed